Pulmonary Arterial Hypertension Clinical Trial NCT02939599
Novartis is sponsoring a clinical research trial available to men and women who are 18 years of age or older with pulmonary arterial hypertension (PAH). PAH is a disorder where individuals have high blood pressure (hypertension) in the arteries of their lungs (pulmonary artery) for no known reason. The pulmonary arteries are the blood vessels responsible for transporting blood from the right side of the heart through the lungs.
Some individuals may go years without knowing they have PAH because symptoms can be mild, nonspecific, or present only when the individual is heavily exercising. Common symptoms include: dyspnea (shortness of breath), chest pain, fainting episodes, tiredness, abdomen pain on the upper right side, a reduced appetite, and an accelerated heartbeat. To learn more about PAH, click here, click here.
The main purpose of this study is to assess the safety, tolerability, pharmacokinetics, and efficacy of QCC374 (an inhaled IPR agonist for the treatment of PAH) in the treatment of pulmonary arterial hypertension in adult patients and to determine if QCC374 has an adequate clinical profile to warrant further clinical development in this indication.
This is a non-confirmatory, randomized, subject and investigator blinded, placebo controlled, two-part study. The treatment duration is 16 weeks for both parts. If you are eligible and agree to participate in the study, you will be treated with QCC374 (the study drug) or a placebo (an inactive drug used to compare its effects to effects of the tested drug) over a 16-week period. Following completion of the 16-week study, you may be eligible to continue to receive QCC374 in a long-term safety extension study.
To see if you may be eligible, click here for a pre-screener/questionnaire.
Find out if there is a PAH clinical study location nearby.
Patients who participate in this trial must meet the following requirements:
- Must be 18 years of age or older
- Must be diagnosed with PAH
- Must have persistent symptoms due to PAH
- Must not be currently pregnant
- Must not been in any other clinical trials in the past six months
Patients who are eligible and decide to enroll in this trial:
- Will receive either study medication or placebo for 16-week period
- Will participate in weekly follow-up phone calls to discuss effects of drug treatment
- Will not be charged to participate
- Will receive compensation for time and travel costs
- May withdraw from the trial at any time, for any reason
To learn more about pulmonary arterial hypertension, click here.
Additional study locations may be listed as they open in the future. We encourage you to share this information via the links at the top of the page.